1DALLAS NA,SAMUEL S,XIA L,et al.Endoglin (CD105):a marker of tumor vasculature and potential target for therapy[J].Clin Cancer Res,2008,14(7):1931-1937.
6DING S,LI C,LIN S,et al.Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions[J].Hum Pathd,2006,37(7):861-866.
9OTTONELLO L,GHIO M,CONTINI P,et al.Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-beta1 by neutrophils:role of the immunoglobulinlike transcript1,sFasL,and sHLA-Ⅰ[J].Transfusion,2007,47(8):1395-1404.
10CASTONGUAY R,WERNER ED,MATTHEWS RG,et al.Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain,inhibits blood vessel formation,and suppresses tumor growth[J].J Biol Chem,2011,286(34):30034-30046.
6Wikstrom P, Lissbrant I F,Stattin P,Egevad I., Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer[J]. Prostate, 2002,51: 268 -275.
7Fonsatti E,Jekunen A P, Kairemo K J, Coral S, Snellman M, Nicotra M R,et al. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model-J-. Clin Cancer Res, 2000,6 : 2037- 2043.
8Benetti A, Berenzi A, Gambarotti M, Garrafa E, Gelati M, Dessy E,et al. Transforming growth factor-betal and CD105 promote the migration of hepatocellular carcinoma derived endothelium [J-. Cancer Res,2008,68:8626- 8634.
9Chiba H,Ishii G,Ito T K,Aoyagi K,Sasaki H,Nagai K,et al. CD105-positive cells in pulmonary arterial blood of adult human lung cancer patients include mesenchymal progenitors[J]. Stem Ceils, 2008,26:2523- 2530.
10Oxmann D, Held-Feindt J, Stark A M, Hattermann K, Yoneda T,Mentlein R. Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype[J]. Oneogene, 2008,27 : 3567 -3575.
1MIKA J, ROJEWSKA E, MAKUCH W, et al. Minocycline reduces the injury-induced expression of prodynorphin and pronociceptin in the dorsal root ganglion in a rat model of neuropathic pain [ J ]. Neuroscience ,2010,165 (4) : 1420 - 1428.
2KAIKKONEN MU, MAATTA AI, YLA-HERTFUALA S, et al. Screening of complement inhibitors: shielded baculoviruses increase the safety and efficacy of gene delivery [ J ]. Mol Ther, 2010,18(5) :987 -992.
3DAS N, BISWAS B, KHERA R. Membrane-bound complement regulatory proteins as biomarkers and potential therapeutic targets for SLE[ J]. Adv Exp Med Biol,2013,735(6) :55 -81.
4WIRSTLEIN P, MIKOLAJCZYK M, SKRZYPCZAK J. Assessment of the transcription levels for the complement activation control system in eutopic cndometrium in women with two or more consecutive miscarriages of unknown etiology [ J ]. Folia Histochem Cytobio1,2010,30,48 (3) :328 - 332.
5KUSNER LL, KAMINSKI HI. The role of complement in experimental autoimmune myasthenia gravis [ J ]. Ann N Y Acad Sei ,2012,1274( 12 ) : 127 - 132.
6BORSOOK D, BECERRA L, Hargreaves R. Biomarkers for chronic pain and analgesia. Part 1 : the need, reality, challenges, and solutions [ J ]. Discov Med ,2011,11 ( 58 ) : 197 - 207.
